Heart Disease News and Research

Latest Heart Disease News and Research

Breast cancer drug Avastin loses FDA support

According to a Food and Drug Administration (FDA) announcement last Friday, the cancer drug Avastin should not be used to treat breast cancer that has spread to other organs because it doesn't help patients enough to justify its risky side effects.

21 Nov 2011

Roche establishes strategic alliance with Cedars-Sinai Medical Center

Roche announced today the establishment of a strategic alliance with Cedars-Sinai Medical Center in Los Angeles for the center to operate as a Roche Molecular Center of Excellence (MCOE) for the next five years.

From Roche Sequencing and Life Science 21 Nov 2011

Health policies, entitlements grab headlines in GOP campaign coverage

Newt Gingrich's health policies are getting a thorough review as his standings in the polls improve. In the background, Mitt Romney blames President Barack Obama for the super committee's difficulties.

21 Nov 2011

Viewpoints: Finding savings in Medicare; The Avastin saga; Changes in health care business

There is no way to wrestle down the deficit without reining in Medicare costs. Ensuring that the program provides quality health care coverage to millions of older and disabled Americans is essential. These goals are not incompatible, but they require a judicious approach to policy making that is depressingly absent in Washington.

21 Nov 2011

State roundup: Provider groups merging - or not

A selection of health policy stories from California, Illinois, Georgia, Connecticut, Minnesota, Michigan and Massachusetts.

21 Nov 2011

The untold stories of children of sperm donors

From Jennifer Lahl and The Center for Bioethics and Culture, producers of the award-winning Eggsploitation (2010), Anonymous Father's Day presents the untold stories of children of sperm donors.

21 Nov 2011

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine.

21 Nov 2011

UTHealth and Memorial Hermann HVI first in Houston to implant FDA approved artificial heart valve

Cardiologists and cardiovascular surgeons at The University of Texas Health Science Center at Houston and Memorial Hermann Heart & Vascular Institute are the first in Houston to implant the artificial heart valve recently approved by the Food and Drug Administration, as well as a newer, smaller version that is part of a clinical trial.

21 Nov 2011

EU's FP7 programme provides €6M grant for Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial

Dr Patricia Kearney, Department of Epidemiology & Public Health, UCC is one of a group of researchers from European Universities who will participate in a new research project investigating current treatment practices for people who suffer from a mildly underactive thyroid gland.

21 Nov 2011

Cambridge Theranostics' liquidators set deadline for offers

Cambridge Theranostics' liquidators have set a deadline of 9 December for offers for the company's business, which includes the intellectual property of its principal product, Ateronon.

21 Nov 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

21 Nov 2011

New blood pressure remote monitoring program for Stamford employees, families

Stamford Hospital has launched a new blood pressure remote monitoring program for its employees and their families in order to detect risk factors for heart disease while helping to improve their overall health.

21 Nov 2011

South Asian cardiac patients three times as likely to require repeat treatment following PCI

South Asian patients with coronary artery disease were almost three times as likely to be readmitted to hospital for further interventional treatment to arterial plaque than their White European counterparts, according to research in the December issue of IJCP, the International Journal of Clinical Practice.

21 Nov 2011

American high school students earn top honors for liver disease and brain injury research

The shortlist of contenders for the highest science honor awarded to American high school students narrowed tonight as the winners of the Siemens Competition in Math, Science & Technology Region 3 Finals were announced.

21 Nov 2011

Three 'critical issues' for Global Fund to consider to ensure 'further success'

While the recent report from a High-Level Independent Review Panel of the Global Fund to Fight AIDS, Tuberculosis and Malaria, "and the corresponding decisions of the Board, mark an important step towards the necessary improvements the Global Fund must make to fulfill its vital mandate in the coming decade and beyond," "the report does not provide direction or solutions on certain critical issues that will define the further success and impact of the Global Fund," Richard Feachem, founding executive director of the Global Fund, writes in a Lancet commentary.

19 Nov 2011

Heart Disease News and Research

Latest Heart Disease News and Research

Breast cancer drug Avastin loses FDA support

Roche establishes strategic alliance with Cedars-Sinai Medical Center

Health policies, entitlements grab headlines in GOP campaign coverage

Viewpoints: Finding savings in Medicare; The Avastin saga; Changes in health care business

State roundup: Provider groups merging - or not

The untold stories of children of sperm donors

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

UTHealth and Memorial Hermann HVI first in Houston to implant FDA approved artificial heart valve

EU's FP7 programme provides €6M grant for Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial

Cambridge Theranostics' liquidators set deadline for offers

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

New blood pressure remote monitoring program for Stamford employees, families

South Asian cardiac patients three times as likely to require repeat treatment following PCI

American high school students earn top honors for liver disease and brain injury research

Three 'critical issues' for Global Fund to consider to ensure 'further success'

Study: Metabolic syndrome biomarkers predict decline in lung function after WTC dust exposure

Roundup: Fla. Medicare HMO closed; Tufts and BCBS resume talks

HRR1 after 6MW test is a strong predictor of clinical worsening in IPAH patients

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Heart Disease News and Research

Latest Heart Disease News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in